Evidence map›Paper›PMID 41056343›Full record

ArticleJournal of medicinal chemistry2025

Optimization of 2,8-Diaryl-1,5-naphthyridines as

Godwin A Dziwornu, Donald Seanego, Stephen Fienberg, Venkata S Sypu, Nicolaas Salomane, Liezl Krugmann, Dale Taylor, Keabetswe Masike, Mathew Njoroge, Nonlawat Boonyalai and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Godwin A DziwornuHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0003-1668-8818
Donald SeanegoHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-8871-5251
Stephen FienbergHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Venkata S SypuHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Nicolaas SalomaneHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Liezl KrugmannHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Dale TaylorHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Keabetswe MasikeHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Mathew NjorogeHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Nonlawat BoonyalaiBiological Chemistry and Drug Discovery, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee DD1 5EH, U.K.
Marcus C S LeeBiological Chemistry and Drug Discovery, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee DD1 5EH, U.K.
Luiz C GodoyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Charisse Flerida PasajeDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Jacquin C NilesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-6250-8796
Gregory S BasarabHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-5684-6046
Lauren B CoulsonHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.ORCID 0000-0003-4699-0428
Sandeep R GhorpadeHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0002-9311-1572
Kelly ChibaleHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0002-1327-4727

Funding

Gates Foundation INV-026505
6 · The paper itself

Abstract

Previously reported antimalarial

Indexed as

AntimalarialsNaphthyridinesPlasmodium falciparumProtein Kinase Inhibitors1-Phosphatidylinositol 4-KinaseAnimalsHumansMalaria, FalciparumMiceMice, Inbred NODMice, SCIDStructure-Activity Relationship1-Phosphatidylinositol 4-KinaseAntimalarialsNaphthyridinesProtein Kinase Inhibitors

Identifiers

PMID41056343
PMCPMC12557380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.